The cardiovascular changes underlying a low cardiac output with exercise in patients with type 2 diabetes mellitus

被引:1
|
作者
Madsen, Per Lav [1 ,2 ,3 ]
Sejersen, Casper [3 ,4 ]
Nyberg, Michael [5 ]
Sorensen, Martin Heyn [6 ]
Hellsten, Ylva [3 ]
Gaede, Peter [6 ]
Bojer, Annemie Stege [1 ,6 ]
机构
[1] Univ Copenhagen, Herlev Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Univ Copenhagen, Dept Nutr Exercise & Sports, August Krogh Sect Human Physiol, Copenhagen, Denmark
[4] Univ Copenhagen, Dept Anaesthesia, Dept Clin Med, Rigshosp, Copenhagen, Denmark
[5] Novo Nordisk, Dept Kidney & Vasc Biol, Global Drug Discovery, Copenhagen, Denmark
[6] Slagelse Naestved Hosp, Dept Endocrinol, Copenhagen, Denmark
关键词
type 2 diabetes mellitus; heart failure with a preserved ejection fraction; exercise intolerance; hypertension; cardiac fibrosis; myocardial blood flow and flow reserve; HUMAN SKELETAL-MUSCLE; LEFT-VENTRICULAR HYPERTROPHY; ISOLATED SYSTOLIC HYPERTENSION; REDUCES ARTERIAL STIFFNESS; LIFELONG PHYSICAL-ACTIVITY; CONGESTIVE-HEART-FAILURE; BLOOD-FLOW REGULATION; PULSE-WAVE VELOCITY; NITRIC-OXIDE; ATHLETES HEART;
D O I
10.3389/fphys.2024.1294369
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The significant morbidity and premature mortality of type 2 diabetes mellitus (T2DM) is largely associated with its cardiovascular consequences. Focus has long been on the arterial atheromatosis of DM giving rise to early stroke and myocardial infarctions, whereas less attention has been given to its non-ischemic cardiovascular consequences. Irrespective of ischemic changes, T2DM is associated with heart failure (HF) most commonly with preserved ejection fraction (HFpEF). Largely due to increasing population ages, hypertension, obesity and T2DM, HFpEF is becoming the most prevalent form of heart failure. Unfortunately, randomized controlled trials of HFpEF have largely been futile, and it now seems logical to address the important different phenotypes of HFpEF to understand their underlying pathophysiology. In the early phases, HFpEF is associated with a significantly impaired ability to increase cardiac output with exercise. The lowered cardiac output with exercise results from both cardiac and peripheral causes. T2DM is associated with left ventricular (LV) diastolic dysfunction based on LV hypertrophy with myocardial disperse fibrosis and significantly impaired ability for myocardial blood flow increments with exercise. T2DM is also associated with impaired ability for skeletal muscle vasodilation during exercise, and as is the case in the myocardium, such changes may be related to vascular rarefaction. The present review discusses the underlying phenotypical changes of the heart and peripheral vascular system and their importance for an adequate increase in cardiac output. Since many of the described cardiovascular changes with T2DM must be considered difficult to change if fully developed, it is suggested that patients with T2DM are early evaluated with respect to their cardiovascular compromise.
引用
下载
收藏
页数:16
相关论文
共 50 条
  • [21] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Scirica, Benjamin M.
    Bhatt, Deepak L.
    Braunwald, Eugene
    Steg, P. Gabriel
    Davidson, Jaime
    Hirshberg, Boaz
    Ohman, Peter
    Frederich, Robert
    Wiviott, Stephen D.
    Hoffman, Elaine B.
    Cavender, Matthew A.
    Udell, Jacob A.
    Desai, Nihar R.
    Mosenzon, Ofri
    McGuire, Darren K.
    Ray, Kausik K.
    Leiter, Lawrence A.
    Raz, Itamar
    Braunwald, Eugene
    Bhatt, Deepak L.
    Scirica, Benjamin M.
    Udell, Jacob A.
    Cavender, Matthew A.
    Desai, Nihar
    Abrahamsen, Timothy
    Grossman, Michelle
    Morin, Suzanne
    Im, Kyungah
    Hoffman, Elaine
    Gabovitch, Daniel
    Pricken, Alexandra
    Mosenzon, Ofri
    Buskila, Alona
    Ohman, Peter
    Hirshberg, Boaz
    Stahre, Christina
    Price, Deborah
    Billing-Clason, Solveig
    Sabel, Karin
    Monyak, John
    Sjostrand, Mikalea
    Wei, Cheryl
    Lu, Jane
    Miller, Elinor
    Raichlen, Joel
    Fitt, Sandy
    Frederich, Robert
    Iqbal, Nayyar
    Donovan, Mark
    Davidson, Jaime A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1317 - 1326
  • [22] Predictors of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Tan, M. C.
    Wong, T. W.
    Chan, Y. M.
    Joseph, A.
    Hejar, A. R.
    Ng, O. C.
    INTERNATIONAL JOURNAL OF COLLABORATIVE RESEARCH ON INTERNAL MEDICINE & PUBLIC HEALTH, 2013, 5 (07) : 492 - 506
  • [23] Cardiovascular event costs in patients with Type 2 diabetes mellitus
    Johnston, Stephen S.
    Sheehan, John J.
    Shah, Manan
    Cappell, Katherine
    Princic, Nicole
    Smith, David
    Kalsekar, Iftekhar
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (12) : 1032 - 1040
  • [24] Empagliflozin and cardiovascular endpoints in patients with type 2 diabetes mellitus
    Guthoff M.
    Der Nephrologe, 2016, 11 (3): : 217 - 218
  • [25] Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
    Fujihara, Kazuya
    Sone, Hirohito
    ANNALS OF VASCULAR DISEASES, 2018, 11 (01) : 2 - 14
  • [26] Reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Nicholls, Stephen J.
    Ryden, Lars
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 : S1 - S1
  • [27] Benefit of combined cardiac rehabilitation on exercise capacity and cardiovascular parameters in patients with type 2 diabetes
    Svacinova, Hana
    Novakova, Marie
    Placheta, Zdenek
    Kohzuki, Masahiro
    Nagasaka, Makoto
    Minami, Naoyoshi
    Dobsak, Petr
    Siegelova, Jarmila
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 215 (01): : 103 - 111
  • [28] MicroRNAs as biomarkers for monitoring cardiovascular changes in Type II Diabetes Mellitus (T2DM) and exercise
    Saini, Volga M.
    Liu, Kaitlyn R.
    Surve, Aishwarya Suryakant
    Gupta, Sanjeev
    Gupta, Ananya
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2022, 21 (02) : 1819 - 1832
  • [29] MicroRNAs as biomarkers for monitoring cardiovascular changes in Type II Diabetes Mellitus (T2DM) and exercise
    Volga M Saini
    Kaitlyn R. Liu
    Aishwarya Suryakant Surve
    Sanjeev Gupta
    Ananya Gupta
    Journal of Diabetes & Metabolic Disorders, 2022, 21 : 1819 - 1832
  • [30] Exercise attenuates the premature cardiovascular aging effects of type 2 diabetes mellitus
    Huebschmann, Amy G.
    Kohrt, Wendy M.
    Regensteiner, Judy G.
    VASCULAR MEDICINE, 2011, 16 (05) : 378 - 390